Microdosing GLP-1 medication — using doses below the standard titration ladder — has moved from a fringe practice to a marketed product line. Noom, Mochi, Hims & Hers, Midi, Ivím, and Ro all now offer or discuss microdosing programmes. The commercial logic is obvious: lower doses cost less and cause fewer side effects. The clinical evidence is much thinner than the marketing implies. This guide covers what microdosing is, who it might suit, and what is and is not established.

Quick Takeaway:

• Microdosing means using GLP-1 doses below the standard approved titration schedule
• It is not an FDA-approved dosing strategy, and evidence is largely observational rather than from randomised trials
• The plausible use cases are side-effect intolerance, cost constraint, and maintenance after a full-dose phase
• Weight loss at sub-therapeutic doses is generally smaller than at approved maintenance doses
• Most microdosing programmes use compounded preparations, which carry their own considerations

Looking for a Better Alternative?

If dose escalation is the problem, provider support matters more than the dosing strategy. CoreAge Rx is our top-rated favorite for GLP-1 weight loss therapy, combining competitive pricing with exceptional customer service, faster medication delivery, and more comprehensive support resources.

Why we recommend CoreAge Rx:

• Lower monthly costs than most competitors ($179–$399 range)
• Faster prescription approval (typically 12–24 hours)
• More extensive provider support included at no extra charge
• Better medication availability during shortages
• Higher patient satisfaction scores (4.7/5)

New Patient Special: Save up to $200 on your first three months. Same-day prescription approval for qualifying patients. Rated 4.7/5 stars by verified customers. No insurance required.

What Microdosing Actually Means

Approved GLP-1 dosing follows a defined escalation schedule: start low, increase every four weeks, reach a target maintenance dose. Semaglutide for weight management titrates to 2.4 mg weekly; tirzepatide escalates through 2.5, 5, 7.5, 10, 12.5, and 15 mg.

Microdosing means deliberately staying below that ladder — remaining at a starter dose indefinitely, using fractional doses between the standard steps, or reducing to a lower dose after reaching maintenance.

It is important to be precise about the distinction. Slow titration — taking longer than four weeks between increases because of side effects — is routine, well-accepted clinical practice. Microdosing as a deliberate long-term strategy of staying below the therapeutic target is a different proposition with a much weaker evidence base.

Who Offers Microdosing

The convergence is striking, and it reflects two commercial realities as much as clinical ones: lower doses cost providers less to supply, and patients who quit because of side effects stop paying.

The Case For Microdosing

There are legitimate scenarios:

1. Side-effect intolerance. A patient who cannot tolerate 5 mg tirzepatide but does well at 2.5 mg is better served staying at 2.5 mg than discontinuing. This is the strongest case, and it is really an argument for individualised dosing rather than microdosing as a distinct strategy.

2. Cost constraint. For patients on tiered pricing, staying at a lower dose costs meaningfully less. Some weight loss sustained over a year beats none at all.

3. Maintenance after full-dose loss. Some patients who have reached their goal reduce dose to maintain rather than continuing at maximum. Weight regain after complete discontinuation is well documented, so a lower maintenance dose is a plausible middle path.

4. Metabolic benefit without maximal loss. Some patients want improvements in glucose control, blood pressure, or metabolic markers rather than maximal weight reduction.

Embla's published position — keeping patients on the lowest effective dose, framed around reducing pharmacy and chronic condition costs — is a coherent version of this argument.

The Case Against

Important: The pivotal trials that established GLP-1 efficacy studied specific maintenance doses. Semaglutide's approximately 15% mean loss at 68 weeks was at 2.4 mg. Tirzepatide's 16.5%–22.4% over 72 weeks was at its approved doses. There is no equivalent trial evidence for sustained sub-therapeutic dosing, and it is not reasonable to assume proportional benefit.

Specific concerns:

• Reduced efficacy. Dose-response relationships in the trials were real. Lower doses generally produced less weight loss.
• No regulatory approval. Microdosing is not an FDA-approved dosing strategy, so you are outside the evidence base and the labelling.
• Compounded dependency. Fractional doses between standard steps typically require compounded preparations, since manufacturer pens deliver fixed increments. That imports all the considerations in our compounded versus brand-name guide.
• Dosing errors. Drawing sub-standard doses from a multi-dose vial increases the risk of measurement error. Dosing mistakes with compounded GLP-1s have been reported to poison control centres.
• Commercial incentive. Providers benefit from lower supply costs and reduced discontinuation. That does not make microdosing wrong, but it does mean the marketing should be read carefully.

How to Approach It Sensibly

If microdosing is being suggested to you, ask:

1. Is this individualised dosing or a product? Staying at a tolerated dose is good medicine. Being sold a "microdose programme" before you have tried standard titration is a commercial decision.
2. What is the exact dose in milligrams? Not "microdose" — the actual figure, in milligrams, and the volume you will inject.
3. Is this compounded or manufacturer product? And if compounded, which pharmacy, and 503A or 503B?
4. What is the plan if it does not work? A microdose that produces no weight loss after three months is money spent for nothing.
5. How is the dose measured? Pre-filled syringe, pen with fixed increments, or drawing from a vial yourself.

Frequently Asked Questions

What is GLP-1 microdosing?

Using GLP-1 doses below the standard approved titration schedule — either remaining at a starter dose long-term, using fractional doses between standard steps, or reducing dose after reaching a maintenance target.

Is microdosing FDA-approved?

No. Microdosing is not an FDA-approved dosing strategy. The pivotal trials establishing efficacy studied specific approved maintenance doses, and there is no equivalent randomised evidence for sustained sub-therapeutic dosing.

Does microdosing still produce weight loss?

It may for some people, particularly those who respond well at lower doses. However, dose-response relationships in the clinical trials were real, and lower doses generally produced less weight loss than approved maintenance doses. Do not expect trial-level results from sub-therapeutic dosing.

Who is microdosing appropriate for?

The most defensible cases are patients who cannot tolerate standard doses, patients for whom cost at higher doses is prohibitive, and patients maintaining after a full-dose phase. It is a clinical decision for your prescriber, not a self-directed choice.

Are there risks specific to microdosing?

Yes. It typically requires compounded preparations, which are not FDA-approved. Drawing non-standard doses from multi-dose vials increases measurement error risk, and dosing errors with compounded GLP-1s have been reported. You are also operating outside the labelled dosing and its evidence base.

Is staying on a lower dose the same as microdosing?

Not quite. Slow titration and holding at a tolerated dose are routine, accepted clinical practice — and often the right answer when side effects are difficult. Microdosing as a marketed programme, entered before standard titration has been attempted, is a different and less evidenced proposition.

Bottom Line

There is a sound clinical principle buried inside the microdosing trend: the right dose is the lowest one that achieves your goal, and staying at a tolerated dose is far better than quitting at an intolerable one.

There is also a commercial trend that has run ahead of the evidence. Microdosing is not FDA-approved, was not the basis of the trials that established these drugs' efficacy, usually requires compounded product, and is being marketed by providers who benefit from selling less drug to patients who stay subscribed longer.

If your prescriber suggests holding at a lower dose because you cannot tolerate more, that is good medicine. If a platform sells you a microdose programme before you have tried standard titration, ask why.

CoreAge Rx includes titration support and unlimited provider messaging at no extra charge — so dose decisions are made clinically, not by what you can afford. All-in pricing from $179–$399.

Medical disclaimer: Informational only, not medical advice. Microdosing is not an FDA-approved dosing strategy. Never adjust your GLP-1 dose without your prescriber's direction. Compounded medications are not FDA-approved products.

Sources: FDA prescribing information and dosing schedules for Wegovy, Ozempic, Zepbound, and Mounjaro; FDA cautions regarding compounded GLP-1 products and dosing errors; provider published microdosing programme pages as cited above.

Date reviewed: August 2026